Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Strides unveils SteriScience as its dedicated arm for sterile injectables

Posted On: 2020-09-14 02:06:35


Strides Pharma Science Limited ('Strides' or 'Company'), a global pharmaceutical company announced today that it is investing in SteriScience Pharma Private Limited ('SteriScience') to make it the Company's dedicated arm for global sterile injectables business. SteriScience has started the development activity for 20+ quick to launch products and expects the first Abbreviated New Drug Application ('ANDA') filing to be achieved within FY21. Furthermore, SteriScience has entered into a Joint Venture ('JV') with Brooks Laboratories Limited ('Brooks') for building a robust carbapenem business with integrated manufacturing capabilities. The transaction with Brooks is subject to approval from the shareholders of Brooks.

Background

As Agila Specialties ('Agila'), Strides operated a sizeable sterile injectable business with nine global manufacturing plants and established capabilities for carbapenems, beta-lactams and oncology. Agila enjoyed a formidable position in the marketplace with significant domain expertise and over 200+ filings in the US with 180+ filings in other regulated markets. At the right strategic opportunity, the business was sold to Mylan Inc. ('Mylan') for an enterprise value of $1.6 billion with ₹605 per share distributed as a special dividend to Strides shareholders, a corporate record for India.

On September 20, 2019, Strides announced that it would re-enter into sterile injectables business post the completion of the Company's non-compete period with Mylan. The non-compete period ended in December 2019. Given the unexpected developments due to Ranitidine product withdrawal from the US markets and COVID-19 outbreak, the Company had put on hold all the new investments. However, the Company retained the option to participate in the injectable platform SteriScience in partnership with the family office of the promoters until December 2020 with a ~54% economic interest.

The investment in SteriScience will allow Strides to leverage its rich expertise and experience in the high-value injectables business. SteriScience is designed for a global foray in sterile injectables leveraging the group's rich experience in the domain. It will be a lighter, faster, and yet more valuable platform with a robust B2C strategy that bodes well with the industry opportunity.

Structure and Investments

Strides and the family office of promoters will partner to infuse capital into SteriScience. The partners will also transfer their current sterile injectable related assets and Intellectual Property (IP) to the platform at cost. The business will require a total investment of ₹4,000 million (₹2,500 million equity and ₹1,500 million debt) until it achieves an operational break-even in the next 24 months. The partners will invest this amount in proportion to their ownership (Strides will contribute ₹1,350 million for a ~54% ownership, while the family office of the promoters will make the remaining investments). The investments are envisaged for the following:

a. Development of the Portfolio

SteriScience has already commenced the development of a compelling portfolio driven by a three-pronged strategy viz. acquired IP with significant cross-market opportunity, in-house development of products and by strategic partnerships with high-quality R&D organizations to in-license late-stage products with a focus on specialty injectables. The Company expects to develop 20+ quick-to-market products and will file its first ANDA within FY21.

b. Joint Venture with Brooks for Carbapenems

SteriScience has entered into a JV with Brooks to carry out manufacturing, marketing and distribution of carbapenems for the global markets. Carbapenems are a class of highly effective antibiotic agents commonly used for the treatment of severe or high-risk bacterial infections. It is a $2 billion+ global opportunity with limited players having dedicated capabilities to manufacture these products. As part of the transaction with Brooks, SteriScience will have a majority economic interest to commercialize four products in the global markets along with the integrated infrastructure to manufacture both drug substance and drug product internally. The broad terms of the JV transaction between SteriScience and Brooks are:

i. SteriScience and Brooks will set up a front-end entity to market carbapenem products in the global markets, including the US, Europe, Canada, and Australia. This front-end entity will also own the IP/ANDAs/dossiers of all the carbapenem products across markets. The economic interest for SteriScience will be ~56%.

ii. SteriScience will invest ₹100 million in the front-end entity for the regulatory filings. The EU Filing for the first product was completed in August 2020.

iii. Subject to the approval from Brooks' shareholders, Brooks shall transfer its EU approved manufacturing facility at Vadodara, India to a Joint Venture Company on a debt-free basis. SteriScience will have ~27% economic interest in this Joint Venture Company and will invest up to ₹400 million over 12-15 months period in this facility to create additional capabilities including the manufacturing of all carbapenem APIs and also to commission a dedicated lyophilization line for Ertapenem.

iv. This manufacturing facility will be an exclusive partner to the front-end entity for the international markets.

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.685.9 as compared to the previous close of Rs. 608.1. The total number of shares traded during the day was 324936 in over 10011 trades.

The stock hit an intraday high of Rs. 693.5 and intraday low of 608. The net turnover during the day was Rs. 216221750.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Welspun Corp Ltd receives orders worth Rs. 1400 crore

SKINN by Titan Launches 'Escapade'

Usher in the festivities with Westside's 'What's Your Festive' Campaign

Tata Chemicals bags 3rd spot in Responsible Business Ranking 2020

Canara HSBC OBC Life Insurance rolls out additional health cover for employees amid COVID-19

TCS Global Survey Finds 90% of Large Enterprises are Maintaining or Increasing Digital Transformation Budgets Amid COVID-19

Makers Laboratories Ltd to acquire Resonance Specialties Ltd

Kaveri Seeds features in Forbes, Asia's Best under A Billion 2020 list, 6th time in the last 10 years

Vedanta Jharsuguda rolls out financial literacy training for its 'Subhalaxmi Co-operative' members

Dabur launches Ghar Ghar Immunity initiative

Zen Technologies Limited completes acquisition of 100% shareholding in Zen Medical Technologies Private Limited

KNR construction Ltd successfully completed sale of KNR Walayar Tollways Pvt Ltd to Cube Highways

Infomerics Valuation and Rating Pvt Ltd reaffirms rating of Dhunseri Ventures Limited

CRISIL reaffirms ratings of Diana Tea Company Limited

BLS wins contract from Republic of Estonia

IndiGrid approves Induction of KKR as a Sponsor

Moody's downgrades IIFL Finance to B2 from B1, outlook stable

Emkay Global Financial Services Ltd board to consider 2nd quarter results on Oct 30, 2020

LTI Recognized as a Great Place to Work™ in the USA

SBI Card inks partnership with American Express

Heritage Foods Limited board to consider Q2, H1 results on Oct 28, 2020

Myanma Foreign Trade Bank chooses Intellect for a scalable, future-proof Digital Transformation

TATA Elxsi Ltd board to consider Q2FY21 results on Oct 14, 2020

Steel Strips Wheels Ltd secures export orders of nearly 9000 wheels

Pritish Nandy Communications wins Best Script at Screenwriters' Award 2020

CRISIL reaffirms ratings of Mahindra and Mahindra Limited

Zydus Wellness Limited board fixes QIP price as Rs. 1690

IDFC First Bank's V Vaidyanathan gifts 1 lakh shares to his former school teacher

Vedanta Ltd board to announce Q1 results on Oct 3, 2020

SBI announces celebratory delights for retail customers

IRCON supported the promotion of culture and heritage by carrying out beautification work on the walls of Bengaluru Railway Station

Chembond Water receives 2020 Best Practices Award from Frost & Sullivan

Symphony introduces world's 1st 'Universal packaged air coolers' for industrial and commercial application

Central Bank of India raises Rs. 254.99 crore through QIP

Refex Industries Ltd to invest in units of RKG Fund - I

Endurance Technologies Ltd board to approve Q2, H1 FY2021 results on Nov 10, 2020

Western Union International Money Transfer Services now available at Alankit Forex India Ltd

Cosmo Films Launches BOPP-Fragranced Packaging Film

India Grid Trust completes acquisition of Jhajjar KT Transco Private Limited

Dhunseri Tea & Industries Ltd enters into MoU for sale of Khetojan Tea Estate

Anuh Pharma Ltd receives approval from WHO for Pyrimcthamine API

Dr Lalchandani Labs Ltd announces increase in capacity for Covid-19 RT-PCR testing

SBI announcement of processing fees waiver on Home Loan

EdgeVerve and Minit Partner to Deliver Actionable Process Intelligence

TCS Wins Four Stevie® Awards at the 2020 International Business Awards

SJVN Limited gets investment approval of 210 MW Luhri HEP and 66 MW Dhaulasidh HEP in Himachal Pradesh

TV Today Network Ltd board to consider Q2, H1 FY2020-21 results on Nov 6, 2020

Pre book with Tanishq and secure your gold rate today

NELCAST Ltd completes Phase II of iron casting project at Pedapariya in Andhra Pradesh

Infosys and Roland-Garros Empower Players, Fans and Media with New Digital Innovations on Court and at Home







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019